Skip to main content

Advertisement

SpringerLink
Log in

Biocon's target factory

  • Bioentrepreneur
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

South Korea's 8-year effort to create an integrated platform for novel target and lead development provides an academic drug discovery model for other emerging economies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Biocon in the context of other Korea's national programs to facilitate drug discovery.
Figure 2: Selection process for the Global Frontier Project and Biocon.
Figure 3: The promise of ARSs as therapeutic targets.
Figure 4: Biocon's team structure is functionally divided between core and external specialist groups.
Figure 5: Biocon's six key criteria for target validation.
Figure 6: Representative discoveries in the core target biology (focusing on ARS biology) and innovative technologies applicable to the processes of drug discovery are shown.
Figure 7: Biocon's therapeutic, diagnostic and technological pipelines.

References

  1. Organisation for Economic Co-operation and Development. OECD Education at a Glance 2014 (OECD Publishing, 2014).

  2. Shin, S.M. et al. Nat. Commun. 8, 15090 (2017).

    Article  Google Scholar 

  3. Park, M.C. et al. Cancer Res. 76, 1044–1054 (2016).

    Article  CAS  Google Scholar 

  4. Choe, K. et al. J. Clin. Invest. 125, 4042–4052 (2015).

    Article  Google Scholar 

  5. Lee, J. et al. Nano Lett. 15, 2938–2944 (2015).

    Article  CAS  Google Scholar 

  6. Yang, A. et al. Science 354, 623–626 (2016).

    Article  CAS  Google Scholar 

  7. Fang, P. et al. Nat. Commun. 6, 6402 (2015).

    Article  CAS  Google Scholar 

  8. Zhou, H., Sun, L., Yang, X.L. & Schimmel, P. Nature 494, 121–124 (2013).

    Article  CAS  Google Scholar 

  9. Son, J. et al. Acta Crystallogr. D Biol. Crystallogr. 69, 2136–2145 (2013).

    Article  CAS  Google Scholar 

  10. Schimmel, P., Tao, J. & Hill, J. FASEB J. 12, 1599–1609 (1998).

    Article  CAS  Google Scholar 

  11. Rock, F.L. et al. Science 316, 1759–1761 (2007).

    Article  CAS  Google Scholar 

  12. Novoa, E.M. et al. Proc. Natl. Acad. Sci. USA 111, E5508–E5517 (2014).

    Article  CAS  Google Scholar 

  13. Park, J.S. et al. Circulation 136, A24036 (2017).

    Google Scholar 

  14. Park, M.C. et al. Proc. Natl. Acad. Sci. USA 109, E640–E647 (2012).

    Article  CAS  Google Scholar 

  15. Ahn, Y.H. et al. Nat. Microbiol. 2, 16191 (2016).

    Article  CAS  Google Scholar 

  16. Kim, S.B. et al. J. Cell Biol. 216, 2201–2216 (2017).

    Article  CAS  Google Scholar 

  17. Ko, Y.G. et al. J. Biol. Chem. 276, 6030–6036 (2001).

    Article  CAS  Google Scholar 

  18. Han, J.M. et al. Cell 149, 410–424 (2012).

    Article  CAS  Google Scholar 

  19. Kim, D.G. et al. FASEB J. 26, 4142–4159 (2012).

    Article  CAS  Google Scholar 

  20. Kwon, N.H. et al. ACS Pharmacol. Transl. Sci. https://doi.org/10.1021/acsptsci.8b00001 (2018).

    Article  CAS  Google Scholar 

  21. Kim, S., You, S. & Hwang, D. Nat. Rev. Cancer 11, 708–718 (2011).

    Article  CAS  Google Scholar 

  22. Choi, J.W. et al. PLoS Genet. 7, e1001351 (2011).

    Article  CAS  Google Scholar 

  23. Choi, J.W. et al. J. Mol. Cell Biol. 4, 164–173 (2012).

    Article  Google Scholar 

  24. Lee, H.S. et al. Biochem. J. 454, 411–416 (2013).

    Article  CAS  Google Scholar 

  25. Park, S.G., Ewalt, K.L. & Kim, S. Trends Biochem. Sci. 30, 569–574 (2005).

    Article  CAS  Google Scholar 

  26. Kang, T. et al. J. Mol. Biol. 423, 475–481 (2012).

    Article  CAS  Google Scholar 

  27. Kim, J.H. et al. Nat. Commun. 8, 732 (2017).

    Article  Google Scholar 

  28. Kim, D.G. et al. Nat. Chem. Biol. 10, 29–34 (2014).

    Article  CAS  Google Scholar 

  29. Jeong, S.J. et al. Exp. Mol. Med. 50, e424 (2018).

    Article  CAS  Google Scholar 

  30. Lee, E.Y. et al. Nat. Immunol. 17, 1252–1262 (2016).

    Article  CAS  Google Scholar 

  31. Kim, J. et al. Nat. Mater. 10, 747–752 (2011).

    Article  CAS  Google Scholar 

  32. Park, J., Oh, S. & Park, S.B. Angew. Chem. Int. Ed. Engl. 51, 5447–5451 (2012).

    Article  CAS  Google Scholar 

  33. Han, S. et al. Adv. Mater. 24, 5924–5929 (2012).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by a Global Frontier Project grant (NRF-M3A6A4-2010-0029785).

Author information

Authors and Affiliations

  1. Thomas X. Neenan, Robert E. Burrier and Sunghoon Kim are at the Medicinal Bioconvergence Research Center (Biocon), Seoul, South Korea,

    Thomas X Neenan, Robert E Burrier & Sunghoon Kim

  2. Sunghoon Kim is in the Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Pharmacy, Seoul National University, Seoul, South Korea.,

    Sunghoon Kim

Authors
  1. Thomas X Neenan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert E Burrier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sunghoon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sunghoon Kim.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Neenan, T., Burrier, R. & Kim, S. Biocon's target factory. Nat Biotechnol 36, 791–797 (2018). https://doi.org/10.1038/nbt.4242

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.4242

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation